Factors associated with osteonecrosis in thai lupus patients: A case control study

Journal of Clinical Rheumatology

Volumn 15, Issue 7, 2009, Pages 345-349

  Uea Areewongsa, Parichat ^a   Chaiamnuay, Sumapa ^a   Narongroeknawin, Pongthorn ^a   Asavatanabodee, Paijit ^a  

^a PHRAMONGKUTKLAO HOSPITAL   (Thailand)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CARDIOLIPIN ANTIBODY; CHLOROQUINE; CYCLOPHOSPHAMIDE; GLUCOCORTICOID; HYDROXYCHLOROQUINE; LIPID; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISOLONE;

ADULT; ARTICLE; BONE RADIOGRAPHY; CASE CONTROL STUDY; CLINICAL ARTICLE; CONTROLLED STUDY; CORTICOSTEROID THERAPY; DISEASE ACTIVITY; DISEASE DURATION; DRUG USE; FEMALE; FEMUR HEAD NECROSIS; FOLLOW UP; GROUPS BY AGE; HUMAN; KIDNEY; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RISK FACTOR; SYSTEMIC LUPUS ERYTHEMATOSUS; THAILAND;

ADULT; ANTIMALARIALS; CASE-CONTROL STUDIES; FEMALE; FEMUR HEAD NECROSIS; FOLLOW-UP STUDIES; GLUCOCORTICOIDS; HUMANS; KIDNEY; LOGISTIC MODELS; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; RETROSPECTIVE STUDIES; THAILAND;

EID: 70350154496     PISSN: 10761608     EISSN: None     Source Type: Journal    
DOI: 10.1097/RHU.0b013e3181ba3423     Document Type: Article

References (34)

1. Harris ED, Ruddy S, Kelley WN. Kelley's textbook of rheumatology. 7th ed. ed. Philadelphia, Pa.: Great Britain ; Elsevier/Saunders: Elsevier; 2005.
2. Gladman DD, Chaudhry-Ahluwalia V, Ibanez D, et al. Outcomes of symptomatic osteonecrosis in 95 patients with systemic lupus erythematosus. J Rheumatol. 2001;28:2226-2229. (Pubitemid 32947867)
3. Rascu A, Manger K, Kraetsch HG, et al. Osteonecrosis in systemic lupus erythematosus, steroid-induced or a lupus-dependent manifestation? Lupus. 1996;5:323-327.
4. Mok CC, Lau CS, Wong RW. Risk factors for avascular bone necrosis in systemic lupus erythematosus. Br J Rheumatol. 1998;37:895-900.
5. Gladman DD, Urowitz MB, Chaudhry-Ahluwalia V, et al. Predictive factors for symptomatic osteonecrosis in patients with systemic lupus erythematosus. J Rheumatol. 2001;28:761-765. (Pubitemid 32246943)
6. Oinuma K, Harada Y, Nawata Y, et al. Osteonecrosis in patients with systemic lupus erythematosus develops very early after starting high dose corticosteroid treatment. Ann Rheum Dis. 2001;60:1145-1148.
7. Houssiau FA, Zeusseu N, Toukap A, Depresseux G, et al. Magnetic resonance imaging-detected avascular osteonecrosis in systemic lupus erythematosus: lack of correlation with antiphospholipid antibodies. Br J Rheumatol. 1998; 37:448-453.
8. Jaovisidha S, Denprechawong R, Suwannalai P, et al. Asymptomatic avascular osteonecrosis of the hip in new patients diagnosed as systemic lupus erythematosus in Ramathibodi Hospital. J Med Assoc Thai. 2007;90:1382-1390.
9. Mont MA, Glueck CJ, Pacheco IH, et al. Risk factors for osteonecrosis in systemic lupus erythematosus. J Rheumatol. 1997;24:654-662.
10. Prasad R, Ibanez D, Gladman D, et al. The role of non-corticosteroid related factors in osteonecrosis (ON) in systemic lupus erythematosus: a nested case-control study of inception patients. Lupus. 2007;16:157-162.
11. Mok MY, Farewell VT, Isenberg DA. Risk factors for avascular necrosis of bone in patients with systemic lupus erythematosus: is there a role for antiphospholipid antibodies? Ann Rheum Dis. 2000;59:462-467.
12. Migliaresi S, Picillo U, Ambrosone L, et al. Avascular osteonecrosis in patients with SLE: relation to corticosteroid therapy and anticardiolipin antibodies. Lupus. 1994;3:37-41.
13. Zonana-Nacach A, Barr SG, Magder LS, et al. Damage in systemic lupus erythematosus and its association with corticosteroids. Arthritis Rheum. 2000;43:1801-1808.
14. Massardo L, Jacobelli S, Leissner M, et al. High-dose intravenous methylprednisolone therapy associated with osteonecrosis in patients with systemic lupus erythematosus. Lupus. 1992;1:401-405.
15. Cozen L, Wallace DJ. Avascular necrosis in systemic lupus erythematosus: clinical associations and a 47-year perspective. Am J Orthop. 1998;27:352-354.
16. Calvo-Alen J, McGwin G, Toloza S, et al. Systemic lupus erythematosus in a multiethnic US cohort (LUMINA): XXIV. Cytotoxic treatment is an additional risk factor for the development of symptomatic osteonecrosis in lupus patients: results of a nested matched case-control study. Ann Rheum Dis. 2006;65:785-790.
17. Fialho SC, Bonfa E, Vitule LF, et al. Disease activity as a major risk factor for osteonecrosis in early systemic lupus erythematosus. Lupus. 2007;16: 239-244. (Pubitemid 46797886)
18. Falaschi F, Ravelli A, Martignoni A, et al. Nephrotic-range proteinuria, the major risk factor for early atherosclerosis in juvenile-onset systemic lupus erythematosus. Arthritis Rheum. 2000;43:1405-1409.
19. Aranow C, Zelicof S, Leslie D, et al. Clinically occult avascular necrosis of the hip in systemic lupus erythematosus. J Rheumatol. 1997;24:2318-2322.
20. Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1997;40:1725.
21. Guzman J, Cardiel MH, Arce-Salinas A, et al. Measurement of disease activity in systemic lupus erythematosus. Prospective validation of 3 clinical indices. J Rheumatol. 1992;19:1551-1558.
22. Miyakis S, Lockshin MD, Atsumi T, et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost. 2006;4:295-306.
23. Crew RJ, Radhakrishnan J, Appel G. Complications of the nephrotic syndrome and their treatment. Clin Nephrol. 2004;62:245-259.
24. Mok CC, Tong KH, To CH, et al. Risk and predictors of arterial thrombosis in lupus and non-lupus primary glomerulonephritis: a comparative study. Medicine (Baltimore). 2007;86:203-209.
25. Parag KB, Somers SR, Seedat YK, et al. Arterial thrombosis in nephrotic syndrome. Am J Kidney Dis. 1990;15:176-177.
26. Kim HJ, Park CH, Kang CM, et al. Arterial thrombosis associated with nephrotic syndrome-a case report and review (adult cases in the English literature). J Korean Med Sci. 1993;8:230-234.
27. Tam LS, Gladman DD, Hallett DC, et al. Effect of antimalarial agents on the fasting lipid profile in systemic lupus erythematosus. J Rheumatol. 2000;27: 2142-2145.
28. Siripaitoon B, Osiri M, Vongthavaravat V, et al. The prevalence of dyslipoproteinemia in Thai patients with systemic lupus erythematosus. Lupus. 2004;13:961-968.
29. Wallace DJ, Linker-Israeli M, Metzger AL, et al. The relevance of antimalarial therapy with regard to thrombosis, hypercholesterolemia and cytokines in SLE. Lupus 1993;2(Suppl 1):S13-S15.
30. Borba EF, Bonfa E. Longterm beneficial effect of chloroquine diphosphate on lipoprotein profile in lupus patients with and without steroid therapy. J Rheumatol. 2001;28:780-785.
31. Espinola RG, Pierangeli SS, Gharavi AE, et al. Hydroxychloroquine reverses platelet activation induced by human IgG antiphospholipid antibodies. Thromb Haemost. 2002;87:518-522.
32. Tsakonas E, Joseph L, Esdaile JM, et al. A long-term study of hydroxychloroquine withdrawal on exacerbations in systemic lupus erythematosus. The Canadian Hydroxychloroquine Study Group. Lupus. 1998;7:80-85.
33. Colwell CW Jr. , Robinson CA, Stevenson DD, et al. Osteonecrosis of the femoral head in patients with inflammatory arthritis or asthma receiving corticosteroid therapy. Orthopedics. 1996;19:941-946.
34. Tektonidou MG, Malagari K, Vlachoyiannopoulos PG, et al. Asymptomatic avascular necrosis in patients with primary antiphospholipid syndrome in the absence of corticosteroid use: a prospective study by magnetic resonance imaging. Arthritis Rheum. 2003;48:732-736.